Sort
10,766 grants matching “checkpoint inhibitor”
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$217,574Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2022 · FD
Project 3: Immune Checkpoint Inhibition Therapy Enhanced by Integrated Photodynamic Treatment and Image Guidance in Preclinical Models of Pancreatic Cancer
$217,561Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2024 · CA
Admin Core
$217,504Elad Ziv · University Of California, San Francisco · P20 · FY2025 · CA
Project-Race and ancestry as predictors of the tumor immune microenvironment and response to immunotherapy
$217,503Elad Ziv · University Of California, San Francisco · P20 · FY2025 · CA
A NOVEL RISK PREDICTION MODEL FOR CHECKPOINT INHIBITOR-RELATED AUTOIMMUNE TOXICITIES
$217,493Vandeventer Place Research Foundation · · FY2020 · Defense Health Agency
Deciphering MDSC function for GBM targeting
$217,469Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · NS
Deciphering MDSC function for GBM targeting
$217,469Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS
Computerized platform for interactive annotation and topological characterization of tumor associated vasculature for predicting response to immunotherapy in lung cancer
$217,410Prateek Prasanna · State University New York Stony Brook · R21 · FY2022 · CA
Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer
$217,388Xin Ming · Wake Forest University Health Sciences · R21 · FY2022 · CA
MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7
$217,355Harvard University (Medical School) · R01 · FY2004 · CA
Nitrosourea-induced growth arrest and apoptotic pathways
$217,289Kevin D Brown · University Of Florida · R01 · FY2007 · CA
Flow Cytometry Core
$217,268Fumito Ito · University Of Southern California · P30 · FY2025 · CA
Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy
$217,163Andrew B. Sharabi · University Of California, San Diego · R21 · FY2022 · CA
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine
$217,150Kavitha Yaddanapudi · University Of Louisville · P20 · FY2024 · GM
Visualizing radiation-induced tumor immune responses
$217,100Anna M Wu · Beckman Research Institute/City Of Hope · R21 · FY2020 · CA
Lectikines for Immunotherapy against Ovarian Cancer
$216,987Nobuyuki Matoba · University Of Louisville · R21 · FY2025 · CA
Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patients
$216,810Fyza Y Shaikh · Johns Hopkins University · K08 · FY2025 · CA
Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patients
$216,810Fyza Y Shaikh · Johns Hopkins University · K08 · FY2022 · CA
Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patients
$216,810Fyza Y Shaikh · Johns Hopkins University · K08 · FY2024 · CA
Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patients
$216,810Fyza Y Shaikh · Johns Hopkins University · K08 · FY2023 · CA
Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patients
$216,810Fyza Y Shaikh · Johns Hopkins University · K08 · FY2021 · CA
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer
$216,691Christy Hagan · University Of Kansas Medical Center · R21 · FY2023 · CA
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
$216,686Dayanidhi Raman · University Of Toledo Health Sci Campus · R21 · FY2022 · CA
Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer
$216,467Aadel Chaudhuri · Washington University · K08 · FY2019 · CA
Diversity Supplement R01CA262388: Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
$216,344Nicholas C Denko · Ohio State University · R01 · FY2022 · CA